Literature DB >> 15539939

siRNAs: mechanism of RNA interference, in vivo and potential clinical applications.

Tom C Karagiannis1, Assam El-Osta.   

Abstract

Small interfering RNAs are currently the most widely used nucleic acid-based sequence-specific gene silencing molecules. These molecules mediate RNA interference--a natural post-transcriptional gene-silencing pathway. Given the high reliability and higher efficiency of small interfering RNA-mediated RNA interference, compared to earlier reverse genetic technologies, this is now the preferred technique in functional genomics. Furthermore, the exquisite specificity and exceptional gene-silencing potency of small interfering RNAs has resulted in intense research related to potential target-specific therapeutic applications of these molecules. This review will discuss the mechanism of RNA interference and applications of the pathway in molecular biology including functional genomics will be overviewed. The article will outline in vivo and potential clinical applications of small interfering RNA molecules.

Mesh:

Substances:

Year:  2004        PMID: 15539939     DOI: 10.4161/cbt.3.11.1309

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  10 in total

Review 1.  Chromatin-bound RNA and the neurobiology of psychiatric disease.

Authors:  J S Tushir; S Akbarian
Journal:  Neuroscience       Date:  2013-07-03       Impact factor: 3.590

Review 2.  The Role of Non-Coding RNAs and Isothiocyanates in Cancer.

Authors:  Samantha L Martin; Kendra J Royston; Trygve O Tollefsbol
Journal:  Mol Nutr Food Res       Date:  2018-05-28       Impact factor: 5.914

3.  Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo.

Authors:  Yin-He Wang; Jin Xiong; Shou-Feng Wang; Yang Yu; Bin Wang; Yi-Xin Chen; Hong-Fei Shi; Yong Qiu
Journal:  Mol Cell Biochem       Date:  2010-04-08       Impact factor: 3.396

4.  Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells.

Authors:  Yin-He Wang; Zhao-Xia Wang; Yong Qiu; Jin Xiong; Yi-Xin Chen; Deng-Shun Miao; Wei De
Journal:  Mol Cell Biochem       Date:  2009-02-20       Impact factor: 3.396

5.  Silencing of AP-4 inhibits proliferation, induces cell cycle arrest and promotes apoptosis in human lung cancer cells.

Authors:  Xuanyu Hu; Wei Guo; Shanshan Chen; Yizhuo Xu; Ping Li; Huaqi Wang; Heying Chu; Juan Li; Yuwen DU; Xiaonan Chen; Guojun Zhang; Guoqiang Zhao
Journal:  Oncol Lett       Date:  2016-04-18       Impact factor: 2.967

6.  Down-regulation of AP-4 inhibits proliferation, induces cell cycle arrest and promotes apoptosis in human gastric cancer cells.

Authors:  Xinghua Liu; Bo Zhang; Yan Guo; Qi Liang; Changyao Wu; Lei Wu; Kaixiong Tao; Guobin Wang; Jianying Chen
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

Review 7.  Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA.

Authors:  Maria Abdul Ghafoor Raja; Haliza Katas; Muhammad Wahab Amjad
Journal:  Asian J Pharm Sci       Date:  2019-02-13       Impact factor: 6.598

8.  The effect of HIF-1alpha siRNA on growth and chemosensitivity of MIA-paca cell line.

Authors:  Lily Yang; Won-Kyung Kang
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

9.  Construction of a recombinant lentivirus-mediated shRNA expression vector targeting the human PSMD10 gene and validation of RNAi efficiency in RPMI‑8226 multiple myeloma cells.

Authors:  Siyue Du; Wenjiao Qin; Haiyan Leng; Zi Chen; Tao Zhang
Journal:  Oncol Rep       Date:  2017-06-30       Impact factor: 3.906

10.  Development of microRNA-21 mimic nanocarriers for the treatment of cutaneous wounds.

Authors:  Sun Young Wang; Hyosuk Kim; Gijung Kwak; Sung Duk Jo; Daeho Cho; Yoosoo Yang; Ick Chan Kwon; Ji Hoon Jeong; Sun Hwa Kim
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.